Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

David Z.I. Cherney, Claire C. J. Dekkers, Sean J. Barbour, Daniel C. Cattran, Abdul Halim Abdul Gafor, Peter J. Greasley, Gozewijn D. Laverman, Soo Kun Lim, Gian Luca Di Tanna, Heather N. Reich, Marc Vervloet, Muh Geot Wong, Ron T. Gansevoort, Hiddo J.L. Heerspink